Smoking remains the most prevalent habit worldwide, and its impact on various health conditions, including asthma, is well documented. However, new findings suggest that biologic therapies for severe asthma show no significant differences in outcomes between ex-smokers and never-smokers. 

Medications such as benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab are used to treat severe asthma. After 52 weeks of treatment, patients—whether ex-smokers or never-smokers—demonstrated significant improvements in asthma control, lung function, reduced exacerbations, and a decreased reliance on oral corticosteroids. 

Inflammatory markers such as exhaled nitric oxide and blood eosinophils decreased in both groups. These results challenge prior assumptions that a substantial smoking history negatively impacts the efficacy of biologic therapies. 

This provides new hope for individuals with severe asthma, regardless of their smoking status.

Source: JACI | [Read Full Story] (https://www.jaci-inpractice.org/article/S2213-2198(25)00046-7/abstract?rss=yes)
